Evaluation of IGF-2 and IGF-2 Receptor Ligand (L1) in a Rat Model of Angelman Syndrome on the EEG and Seizure Phenotype
$212,730
2019
FT2019-003: 2019-2020
Evaluation of IGF-2 and IGF-2 Receptor Ligand (L1) in a Rat Model of Angelman Syndrome on the EEG and Seizure Phenotype
Previous studies by the Alberini lab at NYU show that IGF-2 and L1 rescue neurological symptoms in a mouse model of Angelman syndrome. Preliminary analyses of the AS rat model indicate that EEG and seizure phenotypes are largely similar to those observed in the AS mouse model and AS patients. The aims of this study are to determine whether IGF-2 or L1 alters EEG activity in the AS rat model, evaluate the effect of IGF-2 or L1 on seizure threshold in AS rat model, determine effect of IGF-2 or L1 on sleep and circadian cycling in AS rat model, and assess whether IGF2 or L1 affects behavioral related EEG activity in AS rat model.
Principle Investigator
Anne Anderson, MD